Also, the CYP39A1 G204E carriers had almost a tenfold increased risk for glaucoma-related blindness and a shorter time until blindness (13.7 months) as compared to patients with XFS, who did not carry any CYP39A1 mutations (105.9 months) [126]. The gene discussed is CYP39A1; the disease is exfoliation syndrome.